Medicare Enrolled
Dr. Ostap Melnyk, MD
Hematology & Oncology · San Leandro, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Melnyk from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Melnyk?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Melnyk
Dr. Ostap Melnyk is a hematology & oncology specialist in San Leandro, CA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Melnyk performed 24,582 Medicare services across 1,685 unique beneficiaries.
Between the years covered by Open Payments, Dr. Melnyk received a total of $15,978 from 78 pharmaceutical and/or device companies across 852 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Melnyk is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 22% volume in CA
$15,978 industry payments
Medicare Practice Summary
Medicare Utilization ↗24,582
Medicare services
Top 22% in CA for hematology & oncology
1,685
Unique beneficiaries
$24
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~1,229 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Denosumab injection (Prolia/Xgeva) | 10,380 | $18 | $65 |
| Iron infusion (Monoferric) | 3,000 | $17 | $71 |
| Contrast dye for imaging (iodine-based) A contrast agent containing 300-399 mg/ml of iodine used to enhance imaging studies. It is administered per milliliter to improve the visibility of internal structures. |
2,500 | $0 | $2 |
| MRI contrast dye injection (gadobutrol) | 2,250 | $0 | $2 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,260 | $0 | $7 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,210 | $1 | $89 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
728 | $8 | $32 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
622 | $8 | $17 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
286 | $30 | $142 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
265 | $14 | $82 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
248 | $76 | $251 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
244 | $116 | $353 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
234 | $52 | $254 |
| Telephone medical discussion, 21-30 minutes A telephone conversation with a physician lasting between 21 and 30 minutes. This code covers the time spent discussing medical matters over the phone. |
215 | $87 | $355 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
193 | $141 | $647 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
129 | $20 | $87 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
105 | $1 | $9 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
103 | $69 | $294 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
92 | $69 | $310 |
| Nuclear medicine scan from skull base to mid-thigh with CT A nuclear medicine imaging study covering the area from the base of the skull to the middle of the thighs, performed alongside a CT scan. |
74 | $1,733 | $6,765 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 70 | $288 | $1,133 |
| New patient office visit, complex (60-74 min) | 64 | $179 | $598 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
57 | $1 | $33 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
56 | $168 | $460 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
55 | $29 | $153 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
35 | $72 | $195 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
25 | $157 | $548 |
| CT scan of abdomen and pelvis with contrast A CT scan that uses dye to create detailed images of the abdomen and pelvis. This imaging test helps doctors examine internal organs and structures in these areas. |
23 | $303 | $1,355 |
| CT scan of chest with contrast A computed tomography scan of the chest using a contrast dye to enhance the visibility of internal structures. |
22 | $174 | $916 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
20 | $108 | $288 |
| MRI scan of both breasts A magnetic resonance imaging test that creates detailed pictures of both breasts to help evaluate breast tissue. |
17 | $369 | $1,308 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
15.5% high complexity
73.9% medium
10.7% routine
Industry Payment Transparency
Open Payments through 2024 ↗$15,978
Total received (2018-2024)
Avg $2,283/year across 7 years
Top 25% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
78
Companies
852
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$15,330 (95.9%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$648 (4.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,141
2023
$3,298
2022
$1,631
2021
$1,336
2020
$821
2019
$4,178
2018
$3,572
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
PFIZER INC.
$134
Novartis Pharmaceuticals Corporation
$80
Janssen Biotech, Inc.
$77
JAZZ PHARMACEUTICALS INC.
$77
GlaxoSmithKline, LLC.
$62
Takeda Pharmaceuticals U.S.A., Inc.
$62
Astellas Pharma US Inc
$60
Genmab U.S., Inc.
$60
EMD Serono, Inc.
$59
AstraZeneca Pharmaceuticals LP
$59
E.R. Squibb & Sons, L.L.C.
$39
ABBVIE INC.
$39
ARRAY BIOPHARMA INC
$34
Regeneron Healthcare Solutions, Inc.
$34
Merck Sharp & Dohme LLC
$31
Celgene Corporation
$30
Pharmacosmos Therapeutics Inc.
$30
Daiichi Sankyo Inc.
$27
PUMA BIOTECHNOLOGY, INC.
$26
Gilead Sciences, Inc.
$24
Eisai Inc.
$24
BeiGene USA, Inc.
$22
Lilly USA, LLC
$22
Rigel Pharmaceuticals, Inc.
$16
Boehringer Ingelheim Pharmaceuticals, Inc.
$14
Top 3 companies account for 25.5% of 2024 payments
All-time payments by company (2018-2024) ›
PFIZER INC.
$1,455
Novartis Pharmaceuticals Corporation
$1,280
E.R. Squibb & Sons, L.L.C.
$1,029
Janssen Biotech, Inc.
$999
Amgen Inc.
$921
Astellas Pharma US Inc
$748
AstraZeneca Pharmaceuticals LP
$680
Merck Sharp & Dohme Corporation
$653
Genentech USA, Inc.
$558
Seagen Inc.
$517
Takeda Pharmaceuticals U.S.A., Inc.
$421
Pharmacyclics LLC, An AbbVie Company
$410
Bayer HealthCare Pharmaceuticals Inc.
$407
GENZYME CORPORATION
$400
Daiichi Sankyo Inc.
$389
Lilly USA, LLC
$367
Celgene Corporation
$296
Merck Sharp & Dohme LLC
$287
TESARO, Inc.
$261
Eisai Inc.
$176
EMD Serono, Inc.
$171
Clovis Oncology, Inc.
$166
Gilead Sciences, Inc.
$154
Exelixis Inc.
$144
Boehringer Ingelheim Pharmaceuticals, Inc.
$143
ARRAY BIOPHARMA INC
$140
Jazz Pharmaceuticals Inc.
$136
Kite Pharma, Inc.
$134
Pharmacyclics LLC, an AbbVie Company
$133
Regeneron Healthcare Solutions, Inc.
$128
Taiho Oncology, Inc.
$127
SANOFI-AVENTIS U.S. LLC
$121
JAZZ PHARMACEUTICALS INC.
$112
EISAI INC.
$103
Rigel Pharmaceuticals, Inc.
$102
Pharmacosmos Therapeutics Inc.
$102
Incyte Corporation
$98
Alexion Pharmaceuticals, Inc.
$97
GlaxoSmithKline, LLC.
$80
AbbVie, Inc.
$71
ADC Therapeutics America, Inc.
$67
Genmab U.S., Inc.
$60
Seattle Genetics, Inc.
$60
Myovant Sciences Inc.
$56
Janssen Pharmaceuticals, Inc
$56
Dendreon Pharmaceuticals LLC
$53
Array BioPharma Inc.
$52
Agios Pharmaceuticals, Inc.
$49
Bayer Healthcare Pharmaceuticals Inc.
$47
Myriad Genetic Laboratories, Inc.
$44
Acrotech Biopharma Inc.
$43
BeiGene USA, Inc.
$41
ABBVIE INC.
$39
Acrotech Biopharma LLC
$38
Foundation Medicine, Inc.
$37
Blue Earth Diagnostics Limited
$37
TAIHO ONCOLOGY, INC.
$36
R-Pharm US LLC
$34
Octapharma USA, Inc.
$30
Tactile Systems Technology Inc
$27
PUMA BIOTECHNOLOGY, INC.
$26
TerSera Therapeutics LLC
$25
Spectrum Pharmaceuticals Inc.
$24
SOBI, INC
$24
Puma Biotechnology, Inc.
$24
MorphoSys, US Inc.
$24
Apellis Pharmaceuticals, Inc.
$22
Karyopharm Therapeutics Inc.
$22
Mirati Therapeutics, Inc.
$20
Stemline Therapeutics Inc.
$20
Sirtex Medical Inc
$18
Lexicon Pharmaceuticals, Inc.
$17
SERVIER PHARMACEUTICALS LLC
$17
APO-PHARMA USA, INC.
$16
Fortovia Therapeutics, Inc.
$15
Teva Pharmaceuticals USA, Inc.
$15
Aurobindo Pharma USA, Inc.
$14
Advanced Accelerator Applications
$14
Top 3 companies account for 23.6% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · ALIMTA · ALUNBRIG · Alecensa · Aliqopa · Avastin · Axumin · BELEODAQ · BENDEKA · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · Blincyto · Braftovi · CABLIVI · CABOMETYX · CALQUENCE · CEREZYME · CHANTIX · COSELA · CRESEMBA · Cabometyx · DARZALEX · DEFERIPRONE · Doptelet · ELIQUIS · ELITEK · ELZONRIS · EMPLICITI · ENHERTU · EPKINLY · ERBITUX · ERLEADA · Empaveli · Enhertu · Epkinly · FOUNDATIONONE · FRUZAQLA · Fabhalta · Flexitouch Plus · Folotyn · GAZYVA · GILOTRIF · IBRANCE · ICLUSIG · IDHIFA · IMBRUVICA · IMFINZI · INFLECTRA · INJECTAFER · INLYTA · Imbruvica · Ixempra · JADENU · JAKAFI · JAYPIRCA · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LYNPARZA · Lenvima · Lonsurf · Lutathera · MEKINIST · MONJUVI · MONOFERRIC · MYLOTARG · NINLARO · Nerlynx · Neulasta · Nplate · Nubeqa · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OJJAARA · OPDIVO · ORGOVYX · OXBRYTA · PADCEV · PIQRAY · PRECISETUMOR · PROMACTA · PROVENGE · Padcev · Perjeta · Pomalyst · Prolia · REBLOZYL · RYBREVANT · RYDAPT · Revlimid · Rezlidhia · Rubraca · SANDOSTATIN · SARCLISA · SCEMBLIX · SIR-Spheres Microspheres · SPRYCEL · SUTENT · Soltamox · Stivarga · TABRECTA · TAGRISSO · TASIGNA · TECENTRIQ · TIBSOVO · TUKYSA · Tavalisse · Tecentriq · Tibsovo · ULTOMIRIS · Ultomiris · VARUBI · VENCLEXTA · VERZENIO · VOTRIENT · VYXEOS · Venclexta · Vitrakvi · XALKORI · XARELTO · XGEVA · XOSPATA · XPOVIO · XTANDI · Xermelo · Xofigo · Xospata · Xtandi · ZEJULA · ZEPZELCA · ZYTIGA · Zevalin
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (96%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
186
Per 100K population
11.3
County median income
$126,240
Nearest hospital
WILLOW ROCK CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Melnyk is a mixed practice specialist, with above-average Medicare volume (top 22% in CA), with low-engagement industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Melnyk experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Melnyk performed 10,380 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Melnyk receive payments from pharmaceutical companies?
Yes. Dr. Melnyk received a total of $15,978 from 78 companies across 852 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Melnyk's costs compare to other hematology & oncology specialists in San Leandro?
Dr. Melnyk's average Medicare payment per service is $24. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Melnyk) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in San Leandro
Browse hematology & oncology specialists in San Leandro ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology